Regeneron Pharmaceuticals Inc. (REGN) said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. (DBTX), a 43% premium over its closing price of $2.79 a share in the previous session. Boston-based Decibel Therapeutics is a clinical-stage biotechnology company with a focus on discovering and developing transformative treatments to restore and improve hearing and balance. Regeneron's acquisition price values Decibel Therapeutics at $109 million. Decibel Therapeutics stock is up 36% so far in 2023, compared to a 32.7% increase by the Nasdaq.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.